A Spatial Decision Eye-Tracking Task in Patients with Prodromal and Mild Alzheimer's Disease.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
12 08 2019
Historique:
entrez: 20 8 2019
pubmed: 20 8 2019
medline: 22 7 2020
Statut: ppublish

Résumé

Performances on spatial decision eye-tracking tasks are known to be impaired in patients with moderate Alzheimer's disease (AD), but the clinical relevance of this deficit during earlier stages of AD remains unclear. This study recruited patients with amnestic mild cognitive impairment (aMCI, prodromal AD), patients with mild AD, and age-matched controls from three French memory clinics. Participants' ability to make spatial judgments and decisions was assessed with an eye-tracking system, and cognitive performance on conventional neuropsychological tests was evaluated. We enrolled 26 controls, 25 aMCI patients (median Mini-Mental State Exam [MMSE] 26), and 23 mild-AD patients (median MMSE 23). Patients with mild AD had higher error rates on the spatial decision task than aMCI patients and controls (32.4% versus 23.5%; p < 0.01 and 32.4% versus 22.2%; p < 0.05, respectively), but there were no differences among the groups in anticipation rate or the percentage of express saccades. Additionally, error rates on the spatial decision task were inversely correlated with performance on visual memory tests (immediate and delayed recall on the DMS- 48: r =-0.44, p = 0.0019 and r =-0.43, p = 0.0020, respectively), semantic fluency (r =-0.44, p = 0.0016), and global cognition (MMSE: r =-0.44, p = 0.0019). Performance on the spatial decision task was not correlated with anti-saccades, processing speed, or attentional performance. Patients with mild AD made more errors on a spatial decision task than aMCI patients and controls. We hypothesize that impaired visuospatial judgment may explain these results and distinguish aMCI patients from mild AD patients.

Sections du résumé

BACKGROUND/OBJECTIVE
Performances on spatial decision eye-tracking tasks are known to be impaired in patients with moderate Alzheimer's disease (AD), but the clinical relevance of this deficit during earlier stages of AD remains unclear.
METHODS
This study recruited patients with amnestic mild cognitive impairment (aMCI, prodromal AD), patients with mild AD, and age-matched controls from three French memory clinics. Participants' ability to make spatial judgments and decisions was assessed with an eye-tracking system, and cognitive performance on conventional neuropsychological tests was evaluated.
RESULTS
We enrolled 26 controls, 25 aMCI patients (median Mini-Mental State Exam [MMSE] 26), and 23 mild-AD patients (median MMSE 23). Patients with mild AD had higher error rates on the spatial decision task than aMCI patients and controls (32.4% versus 23.5%; p < 0.01 and 32.4% versus 22.2%; p < 0.05, respectively), but there were no differences among the groups in anticipation rate or the percentage of express saccades. Additionally, error rates on the spatial decision task were inversely correlated with performance on visual memory tests (immediate and delayed recall on the DMS- 48: r =-0.44, p = 0.0019 and r =-0.43, p = 0.0020, respectively), semantic fluency (r =-0.44, p = 0.0016), and global cognition (MMSE: r =-0.44, p = 0.0019). Performance on the spatial decision task was not correlated with anti-saccades, processing speed, or attentional performance.
CONCLUSIONS
Patients with mild AD made more errors on a spatial decision task than aMCI patients and controls. We hypothesize that impaired visuospatial judgment may explain these results and distinguish aMCI patients from mild AD patients.

Identifiants

pubmed: 31424412
pii: JAD190549
doi: 10.3233/JAD-190549
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

613-621

Auteurs

Brice Laurens (B)

Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France.

Vincent Planche (V)

Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France.

Stéphanie Cubizolle (S)

Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.

Léa Declerck (L)

Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.

Sandrine Dupouy (S)

Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France.

Maïté Formaglio (M)

Département de Neurologie cognitive et de Neuro-ophtalmologie, Université Lyon 1 et Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France.

Lejla Koric (L)

Département de Neurologie et de Neuropsychologie, Aix Marseille Université, Assistance Publique des Hôpitaux de Marseille, Marseille, France.

Magali Seassau (M)

CogCharonne, Paris, France.

Caroline Tilikete (C)

Département de Neurologie cognitive et de Neuro-ophtalmologie, Université Lyon 1 et Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France.

Alain Vighetto (A)

Département de Neurologie cognitive et de Neuro-ophtalmologie, Université Lyon 1 et Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France.

Mathieu Ceccaldi (M)

Département de Neurologie et de Neuropsychologie, Aix Marseille Université, Assistance Publique des Hôpitaux de Marseille, Marseille, France.

Françcois Tison (F)

Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France.
CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH